Shorla wins FDA approval for leukaemia drug

The US Food and Drug Administration (FDA) has approved Shorla Pharma’s oncology drug for the treatment of leukaemia. The company, which trades as Shorla Oncology, was established in 2018 by Sharon Cunningham and Orlaith Ryan. The newly approved drug, Nelarabine Injection, is designed to treat T-cell acute lymphoblastic leukaemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL).

Read more at: